This suggests that clinician choices can be directed by the promotion of company data, and potentially calls into question a clinician's choice for his or her patient in the context of a clinical trial. To then link this to the success or otherwise of an individual investigator's career is simply wrong. It is in this context that the language surrounding the corporations manufacturing these agents and the use of the figure demonstrating their relative stock price is both inappropriate and irrelevant to the scientific discussion at hand.
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In myeloma over the last 5 years, we have been fortunate to see the rapid translation of bench-to-bedside research with a constructive partnership between academia, patient advocacy, the National Cancer Institute, the Food and Drug Administration and the pharmaceutical industry. Hard work coupled with a strong sense of collaboration, integrity and the unanimous goal of improving patient survival has underpinned this effort. It is important to recognize that, while great progress has been made in multiple myeloma, the disease remains fatal and a great deal still needs to be done. This will require continued team work if progress is to be maintained. The initial part of the editorial addresses an important scientific debate as part of this ongoing research. In contrast, the remainder conveys a message that is at odds with both the reality and goal of our collective mission.
Reply to the research mission in myeloma by Richardson et al. Although by definition the purpose of editorials is to provoke discussion, I share the authors' indignation 1 with the implications regarding research clinicians' motivations and the influence of corporate rhetoric they have surmized my editorial to contain. 2 This was not what I intended to convey, and I am grateful that they have taken the time to correct these misconceptions. In response I acknowledge here the fact that not only research clinicians, but all interested health care professionals (including those in the pharmaceutical industry, regulatory agencies, philanthropic organizations and medical education companies) involved in myeloma clinical trials have a common, unifying and over-riding goal of helping patients.
I agree with the authors that in many recent trials a higher complete response (CR) rate is associated with a survival advantage.
3-8 I share the view that the introduction of new agents in myeloma has significantly improved overall survival. The concern I meant to raise was that the relationship between CR and improved overall survival (OS) is not consistent, and this becomes more apparent when one considers trials in which a higher response is associated with a higher early mortality, and/ or at best, no improvement in survival. [8] [9] [10] [11] [12] [13] [14] [15] Finally, and unfortunately the statement 'the increase in the CR (in the VISTA trial) (odds ratio 11) was not accompanied by an equally dramatic prolongation of OS (hazard ratio 0.6)' is poorly phrased. There is no standard by which one can compare an odds ratio for CR to a hazard ratio for OS. Given how difficult it has been historically to improve upon the results with MP, and the conflicting results of the various MPT vs MP trials, the clear survival advantage seen with MP-Bortezomib in the VISTA trial is truly remarkable, and by far the most important take-home message. It is not appropriate to directly contrast the results of the E4A03 and VISTA studies (which I agree are both excellent). The contrast I tried to make in the editorial was in the reaction to these trials of stock analysts (whose obtrusive presence at the meeting has recently been noted 16 ), who appear to place an excessively high value on improvements in CR. In my opinion this is not always appropriate, and a more balanced approach is warranted, with better surrogates (for example, molecular CR, suppression of cytogenetic abnormalities) for OS needed. A few studies have reported that AML1-MTG8 expression levels in bone marrow (BM) are 1-to 3-log higher than those in peripheral blood (PB) when detected by quantitative PCR methods in acute myeloid leukemia (AML) with the t(8;21) translocation. [1] [2] [3] However, the relationship between BM and PB is retained at any time during the clinical course is unknown. Here we present a patient with t(8;21) AML who demonstrated isolated ovarian relapse after allogeneic BM transplantation (BMT). AML1-MTG8 chimeric transcripts could be repeatedly detected in both BM and PB during the clinical course. Moreover, the AML1-MTG8 expression levels detected by real-time quantitative (RQ)-PCR methods in PB were higher than those in BM before and at the time of the extramedullary relapse (EMR). Thus, we propose that the presence of EMR is responsible for repeated detection of minimal residual disease (MRD) and discuss the clinical significance of different AML1-MTG8 expression levels between BM and PB for the diagnosis of isolated EMR.
A 22-year-old woman was diagnosed with AML (FrenchAmerican-British (FAB) subtype M2) with thoracic vertebrae involvement in March 1998. Cytogenetic evaluation revealed the t(8;21)(q22;q22) chromosomal translocation. She achieved complete remission (CR) with induction chemotherapy and
